106567-41-3Relevant articles and documents
RADIATION CURABLE INKJET INKS FOR INTERIOR DECORATION
-
Paragraph 0289; 0291-0292, (2020/08/13)
A radiation curable inkjet ink containing at least one or two compounds selected from the group consisting of a polymerizable compound including a vinylether group or a vinylamide group, an amine synergist including an alkanolamine group or a dimethyl ben
ACYLPHOSPHINEOXIDE INITIATORS
-
Paragraph 0212; 0213, (2020/01/24)
An acyl phosphine oxide initiator wherein the acyl group is selected from the group consisting of a benzoyl group substituted by an urea group or an oxalylamide group; a 2,6-dimethyl benzoyl group substituted in position 3 by an urea group or an oxalylami
ACYLPHOSPHINE OXIDE PHOTOINITIATORS
-
Paragraph 0242; 0243; 0244, (2017/12/14)
Thiol modified acylphosphine oxide photoinitiators exhibiting improved smell and extractability are disclosed. Also disclosed is a UV curable inkjet ink containing an acylphosphine oxide photoinitiator and a polymerizable compound, wherein the acylphosphi
N-heteroaryl aryl-substituted thienyl-furyl-and pyrrolyl-sulfonamides and derviatives thereof that modulate the activity of endothelin
-
, (2008/06/13)
Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically-acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit the activity of endothelin are also provided.
Endothelin antagonists: Substituted mesitylcarboxamides with high potency and selectivity for ET(A) receptors
Wu, Chengde,Decker, E. Radford,Blok, Natalie,Bui, Huong,Chen, Qi,Raju,Bourgoyne, Andree R.,Knowles, Vippra,Biediger, Ronald J.,Market, Robert V.,Lin, Shuqun,Dupré, Brian,Kogan, Timothy P.,Holland, George W.,Brock, Tommy A.,Dixon, Richard A. F.
, p. 4485 - 4499 (2007/10/03)
We have previously disclosed the discovery of 2,4-disubstituted anilinothiophenesulfonamides with potent ET(A)-selective endothelin receptor antagonism and the subsequent identification of sitaxsentan (TBC11251, 1) as a clinical development compound (Wu et al. J. Med. Chem. 1997, 40, 1682 and 1690). The orally active 1 has demonstrated efficacy in a phase II clinical trial of congestive heart failure (Givertz et al. Circulation 1998, 98, Abstr. 3044) and was active in rat models of myocardial infarction (Podesser et al. Circulation 1998, 98, Abstr. 2896) and acute hypoxia-induced pulmonary hypertension (Chen et al. FASEB J. 1996, 10 (3), A104). We now report that an additional substituent at the 6-position of the anilino ring further increases the potency of this series of compounds. It was also found that a wide range of functionalities at the 3-position of the 2,4,6-trisubstituted ring increased ETA selectivity by ~10-fold while maintaining in vitro potency, therefore rendering the compounds amenable to fine-tuning of pharmacological and toxicological profiles with enhanced selectivity. The optimal compound in this series was found to be TBC2576 (7u), which has ~10- fold higher ETA binding affinity than 1, high ET(A)/ET(B) selectivity, and a serum half-life of 7.3 h in rats, as well as in vivo activity.
